Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (268)	1/31/1998 10:57:00 PM
From: Cacaito	Respond to of 507

Technically, as per TC-2000, BOP shows heavy accumulation, a positiv divergence from price drop ($29 to $19). OBV (9,18, 36 days) all are consistent with accumalation (another positve divergence). Money Stream positive divergence long term. But negative in short term (reflecting recent drop). This is in big contrast to the heavily shorted ORG (another Sturza target). NVX is also heavily shorted. If FDA approval comes by, the price will skyrocket (my view). Does anybody knows when will the corresponding FDA panel meeting be? Or is just waiting for approval ? did they got FDA panel recommedation ? favor? contra?

To: Cacaito who wrote (268)	2/1/1998 8:53:00 PM
From: andy harrison	Respond to of 507

If you are interested in the potential for GBS and what it will do for NVX, you should check out their work on Menigitis vaccines. The bears refuse to view NVX for anything other than a DTaP company and that will start to get them into trouble in the he future. IMHO, never have a bunch of bears been led by as a blind leader who attempted to drive NVX stock down to $3/share over 3 years ago and failed miserably. Interesting how you seemed to change your tone after you read the entire batch of postings on the board. Only time will tell but I remain entirely confident in my decision to be very long NVX.